Intellia Therapeutics Inc is trading 5% up at $12.72 in pre-market, rebounding after recent weakness following the disclosure of positive clinical data.
- The company reported positive results from its Phase 3 HAELO trial for lonvo-z, a treatment for hereditary angioedema (HAE), which demonstrated an 87% reduction in attacks and met all key endpoints.
- The stock's upward momentum is further supported by a broader risk-on rally across U.S. equity markets.